NEW YORK (360Dx) – Novacyt today announced regulatory actions by US and Chinese regulators for two of its products.

In the US, the firm has registered its Novaprep HQ+ Orange vial as a class I device with the US Food and Drug Administration. Providers who can qualify the vial for cytology or molecular use in the US can now purchase the product. Novacyt plans to seek a commercialization partner for the Novaprep vial and media system, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.